Forte Biosciences Stock Z Score
| FBRX Stock | USD 0.73 0.05 6.41% |
Forte | Z Score |
Forte Biosciences Company Z Score Analysis
Forte Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Forte Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Forte Biosciences is extremely important. It helps to project a fair market value of Forte Stock properly, considering its historical fundamentals such as Z Score. Since Forte Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Forte Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Forte Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Forte Biosciences has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Forte Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forte Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forte Biosciences could also be used in its relative valuation, which is a method of valuing Forte Biosciences by comparing valuation metrics of similar companies.Forte Biosciences is currently under evaluation in z score category among related companies.
Forte Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Forte Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Forte Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Forte Biosciences' value.| Shares | State Street Corporation | 2023-12-31 | 41.7 K | Goldman Sachs Group Inc | 2023-12-31 | 41.5 K | Two Sigma Investments Llc | 2023-12-31 | 41 K | Northern Trust Corp | 2023-12-31 | 26.9 K | Two Sigma Advisers, Llc | 2023-12-31 | 24.8 K | Group One Trading, Lp | 2023-12-31 | 15.8 K | Two Sigma Securities, Llc | 2023-12-31 | 15.4 K | Aries Wealth Management | 2023-12-31 | 13 K | Hsbc Holdings Plc | 2023-12-31 | 10.7 K | Tybourne Capital Management (hk) Ltd | 2023-12-31 | 3.6 M | Perceptive Advisors Llc | 2023-12-31 | 3.3 M |
Forte Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | (10.19 M) | ||||
| Shares Outstanding | 36.39 M | ||||
| Shares Owned By Insiders | 10.92 % | ||||
| Shares Owned By Institutions | 56.17 % | ||||
| Number Of Shares Shorted | 34.1 K | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (31.48 M) | ||||
| Cash And Equivalents | 38.55 M | ||||
| Cash Per Share | 1.89 X | ||||
| Current Ratio | 25.67 X | ||||
| Book Value Per Share | 0.97 X | ||||
| Cash Flow From Operations | (28.71 M) | ||||
| Short Ratio | 1.02 X | ||||
| Earnings Per Share | (1.00) X | ||||
| Target Price | 2.88 | ||||
| Beta | 1.66 | ||||
| Market Capitalization | 26.93 M | ||||
| Total Asset | 38.98 M | ||||
| Retained Earnings | (118.52 M) | ||||
| Working Capital | 34.66 M | ||||
| Net Asset | 38.98 M |
About Forte Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Forte Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forte Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forte Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Forte Biosciences Piotroski F Score and Forte Biosciences Valuation analysis. For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Forte Stock analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Forte Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Forte Biosciences. If investors know Forte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Forte Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Return On Assets (0.50) | Return On Equity (0.85) |
The market value of Forte Biosciences is measured differently than its book value, which is the value of Forte that is recorded on the company's balance sheet. Investors also form their own opinion of Forte Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Forte Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Forte Biosciences' market value can be influenced by many factors that don't directly affect Forte Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Forte Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Forte Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Forte Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.